Dr. Udai Singh has been in academia for 22 years; presently as Assistant Director for Sterile Cell Sorting Core facilities at University of South Carolina, School of Medicine, Columbia, South Carolina.
Dr. Singh’s extensive research focuses on cellular and mucosal immunology, especially on inflammatory bowel disease (IBD) and inflammation. Dr. Singh has published over 60 peer-reviewed papers in the area of inflammation as it relates to autoimmune disease, intestinal inflammation and immune responses. Dr. Singh demonstrated for the first time that anti-CXCL10 (chemokine) Ab treatment abrogated colitis in IL-10-/- mice.
Dr. Singh is studying the immune response and demonstrating that polyphenols such as resveratrol can enhance SIRT-1 expression in the lamina propria lymphocytes and down regulate NF-kB activation, leading to decreased inflammation in the colon. Dr. Singh is investigating the mechanisms underlying the effects of CAM compounds on inflammation and IBD resulting in subsequent lectures, multiple publications and a patent. Dr. Singh is a principal investigator in many research proposals while directing the cell-processing unit of GIOSTAR.